[go: up one dir, main page]

PE20160665A1 - Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x - Google Patents

Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x

Info

Publication number
PE20160665A1
PE20160665A1 PE2015002397A PE2015002397A PE20160665A1 PE 20160665 A1 PE20160665 A1 PE 20160665A1 PE 2015002397 A PE2015002397 A PE 2015002397A PE 2015002397 A PE2015002397 A PE 2015002397A PE 20160665 A1 PE20160665 A1 PE 20160665A1
Authority
PE
Peru
Prior art keywords
receptor
farnesoid
conjugates
modulators
amino acids
Prior art date
Application number
PE2015002397A
Other languages
English (en)
Inventor
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50721801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of PE20160665A1 publication Critical patent/PE20160665A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS 11-HIDROXILO DE ACIDOS BILIARES DE FORMULA (I) O UN CONJUGADO DE AMINOACIDO FARMACEUTICAMENTE ACEPTABLE DEL MISMO DONDE R1 ES HIDROXILO; R2, R3, R4, R5 Y R6 SON TAL COMO SE DEFINEN EN LA DESCRIPCION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR X FERNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, HEPATICA CRONICA, METABOLICA
PE2015002397A 2013-05-14 2014-05-14 Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x PE20160665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361823169P 2013-05-14 2013-05-14

Publications (1)

Publication Number Publication Date
PE20160665A1 true PE20160665A1 (es) 2016-08-07

Family

ID=50721801

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002397A PE20160665A1 (es) 2013-05-14 2014-05-14 Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
PE2020000355A PE20200844A1 (es) 2013-05-14 2014-05-14 Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020000355A PE20200844A1 (es) 2013-05-14 2014-05-14 Derivados 11-hidroxil-6-sustituidos de acidos biliares y conjugados de aminoacidos de los mismos como moduladores de receptores farnesoides x

Country Status (37)

Country Link
US (7) US9611289B2 (es)
EP (4) EP3848038B1 (es)
JP (2) JP6326131B2 (es)
KR (1) KR102229952B1 (es)
CN (2) CN105377870B (es)
AU (1) AU2014267324B2 (es)
BR (1) BR112015028399B1 (es)
CA (1) CA2912139C (es)
CL (2) CL2015003344A1 (es)
CR (1) CR20150643A (es)
CY (1) CY1122614T1 (es)
DK (4) DK3360881T3 (es)
EA (1) EA030152B1 (es)
ES (4) ES2671427T3 (es)
GT (1) GT201500324A (es)
HR (1) HRP20180931T1 (es)
HU (1) HUE037996T2 (es)
IL (2) IL242555B (es)
LT (1) LT2997035T (es)
MA (1) MA38647B1 (es)
ME (1) ME03082B (es)
MX (1) MX352065B (es)
MY (1) MY187886A (es)
NI (1) NI201500160A (es)
PE (2) PE20160665A1 (es)
PH (1) PH12015502576B1 (es)
PL (3) PL2997035T3 (es)
PT (3) PT3360881T (es)
RS (1) RS57372B1 (es)
SA (1) SA515370140B1 (es)
SG (1) SG11201509352XA (es)
SI (3) SI3360881T1 (es)
SM (1) SMT201800326T1 (es)
TN (1) TN2015000497A1 (es)
TR (1) TR201809041T4 (es)
UA (1) UA118673C2 (es)
WO (1) WO2014184271A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
HRP20230170T1 (hr) * 2014-05-29 2023-03-31 Bar Pharmaceuticals S.R.L. Derivati kolana za uporabu u liječenju i/ili prevenciji bolesti povezanih s fxr i tgr5/gpbar1
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
PT3221331T (pt) 2014-11-19 2019-12-23 Nzp Uk Ltd Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediários para a produção de moduladores de fxr esteroidais
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
CN107108687B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
US10208081B2 (en) * 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
CA2976056C (en) * 2015-02-06 2024-02-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
KR20170125927A (ko) * 2015-03-09 2017-11-15 인터셉트 파마슈티컬즈, 인크. 골밀도의 조절 방법
CN107531741A (zh) 2015-03-10 2018-01-02 美莱斯股份有限公司 氟化和烷基化胆酸
CA2979399A1 (en) * 2015-03-13 2016-09-22 Salk Institute For Biological Studies Treating latent autoimmune diabetes of adults with farnesoid x receptor agonists to activate intestinal receptors
AU2016242861B2 (en) 2015-03-31 2020-08-20 Enanta Phamraceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CR20170456A (es) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapias combinadas
WO2016168553A1 (en) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Deuterated obeticholic acid
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106478759A (zh) * 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
JP6824966B2 (ja) * 2015-09-21 2021-02-03 インターセプト ファーマシューティカルズ， インコーポレイテッド 肝臓の再生を促進する方法
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
PH12018550120B1 (en) * 2016-01-28 2023-03-15 Chia Tai Tianqing Pharmaceutical Group Co Ltd Steroid derivative fxr agonist
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112018068278B1 (pt) * 2016-03-11 2023-12-19 Intercept Pharmaceuticals, Inc Derivado de 3-desóxi, ácido livre, sal e conjugado de aminoácido, composição farmaceutica compreendendo o referido composto e seu uso
US10369160B2 (en) 2016-04-13 2019-08-06 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
BR112019010798A2 (pt) 2016-11-29 2019-10-01 Enanta Pharm Inc processo para preparação de derivados de ácidos biliares de sulfonilureia
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
EP3585374B1 (en) 2017-02-21 2023-07-19 Genfit Combination of a ppar agonist with a fxr agonist
JP2020509001A (ja) * 2017-02-23 2020-03-26 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体及びマイクロバイオームの医薬組成物並びにその使用
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
US10676500B2 (en) 2017-04-07 2020-06-09 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
WO2018226724A1 (en) * 2017-06-05 2018-12-13 Intercept Pharmaceuticals, Inc. Treatment and prevention of diabetic eye diseases with a bile acid derivatives
WO2018237350A1 (en) * 2017-06-23 2018-12-27 Intercept Pharmaceuticals, Inc. METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES
BR112020001362A2 (pt) 2017-07-24 2020-08-11 Intercept Pharmaceuticals, Inc. derivados de ácido biliar isotopicamente marcados
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN109182451B (zh) * 2018-08-21 2021-06-11 四川大学 细胞色素cyp3a7酶的新型特异性探针反应及其应用
HRP20240265T1 (hr) 2019-01-15 2024-05-10 Gilead Sciences, Inc. Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CA3142358A1 (en) * 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CA3139291A1 (en) 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
CN110540955B (zh) * 2019-08-28 2021-09-17 北京协同创新研究院 一种提高分化细胞中nrob2基因表达量的方法
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2022233398A1 (en) * 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
WO2025059651A1 (en) * 2023-09-14 2025-03-20 The Regents Of The University Of California Bile salt modification to prevent and treat enteric disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080775A (en) * 1934-08-22 1937-05-18 Celanese Corp Shedding mechanism for circular looms
US2802775A (en) * 1953-05-29 1957-08-13 Merck & Co Inc 11 alpha-hydroxylation of steroids by aspergillus ochraceus
JPS59205396A (ja) * 1983-05-09 1984-11-20 Kuraray Co Ltd １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
ITMI20021532A1 (it) * 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ES2609395T5 (es) * 2004-03-12 2021-08-06 Intercept Pharmaceuticals Inc Tratamiento de la fibrosis usando ligandos de Fxr
AU2007265457C1 (en) * 2006-06-27 2012-11-29 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物

Also Published As

Publication number Publication date
ME03082B (me) 2019-01-20
MA38647B1 (fr) 2019-05-31
DK3360881T3 (da) 2021-03-15
IL272718A (en) 2020-04-30
PT3360881T (pt) 2021-02-19
EP2997035B1 (en) 2018-03-28
US20230233581A1 (en) 2023-07-27
US10532061B2 (en) 2020-01-14
EP2997035A1 (en) 2016-03-23
EP3360881A1 (en) 2018-08-15
SI2997035T1 (sl) 2018-10-30
SI3360881T1 (sl) 2021-06-30
CA2912139C (en) 2021-04-20
BR112015028399B1 (pt) 2021-11-16
US20190209586A1 (en) 2019-07-11
IL242555A0 (en) 2016-02-01
EP3360882A1 (en) 2018-08-15
ES2843737T3 (es) 2021-07-20
PT3360882T (pt) 2021-02-12
HUE037996T2 (hu) 2018-09-28
AU2014267324A1 (en) 2015-11-26
PE20200844A1 (es) 2020-08-18
HK1221471A1 (zh) 2017-06-02
US20200297739A1 (en) 2020-09-24
ES2671427T3 (es) 2018-06-06
LT2997035T (lt) 2018-08-10
US9611289B2 (en) 2017-04-04
MX352065B (es) 2017-11-08
PH12015502576B1 (en) 2018-09-12
CA2912139A1 (en) 2014-11-20
CN105377870B (zh) 2018-04-03
EP3848038A1 (en) 2021-07-14
DK3848038T3 (da) 2023-02-06
HK1253326A1 (zh) 2019-06-14
DK2997035T3 (en) 2018-07-02
IL272718B (en) 2020-11-30
KR102229952B1 (ko) 2021-03-22
CN108245523B (zh) 2021-03-26
TN2015000497A1 (en) 2017-04-06
SA515370140B1 (ar) 2017-04-11
PL3360882T3 (pl) 2021-10-25
CN108245523A (zh) 2018-07-06
UA118673C2 (uk) 2019-02-25
PL2997035T3 (pl) 2018-10-31
US20170216316A1 (en) 2017-08-03
JP2018127481A (ja) 2018-08-16
NZ714082A (en) 2021-02-26
WO2014184271A1 (en) 2014-11-20
CN105377870A (zh) 2016-03-02
SG11201509352XA (en) 2015-12-30
CL2015003344A1 (es) 2016-07-15
EA030152B1 (ru) 2018-06-29
EP2997035B8 (en) 2018-05-23
CY1122614T1 (el) 2020-07-31
ES2847002T3 (es) 2021-07-30
IL242555B (en) 2020-04-30
EP3360881B1 (en) 2020-12-09
US20140371190A1 (en) 2014-12-18
CR20150643A (es) 2016-06-01
BR112015028399A2 (pt) 2017-07-25
PH12015502576A1 (en) 2016-02-29
AU2014267324B2 (en) 2017-11-02
TR201809041T4 (tr) 2018-07-23
US11000532B2 (en) 2021-05-11
GT201500324A (es) 2017-09-28
PL3360881T3 (pl) 2021-11-15
DK3360882T3 (da) 2021-03-08
CL2016001809A1 (es) 2017-01-27
US20240398834A1 (en) 2024-12-05
EP3360882B1 (en) 2020-12-09
EA201592055A1 (ru) 2016-11-30
KR20160007586A (ko) 2016-01-20
SMT201800326T1 (it) 2018-07-17
JP2016518429A (ja) 2016-06-23
MY187886A (en) 2021-10-26
RS57372B1 (sr) 2018-08-31
US20210228599A1 (en) 2021-07-29
ES2936638T3 (es) 2023-03-21
HRP20180931T1 (hr) 2018-10-05
NI201500160A (es) 2016-01-04
SI3360882T1 (sl) 2021-06-30
PT2997035T (pt) 2018-07-18
JP6326131B2 (ja) 2018-05-16
EP3848038B1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
PE20160665A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
AR110299A1 (es) Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
CY1122500T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
BR112012000763B8 (pt) compostos derivados de piridin-4-il, composição farmacêutica, e, usos de um composto
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні